146 related articles for article (PubMed ID: 36475814)
21. Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT.
Vees H; Steiner C; Dipasquale G; Chouiter A; Zilli T; Velazquez M; Namy S; Ratib O; Buchegger F; Miralbell R
Radiat Oncol; 2012 Aug; 7():134. PubMed ID: 22873771
[TBL] [Abstract][Full Text] [Related]
22. Patterns of lymph node positivity on
McClinton C; Niroumand M; Sood S; Shah V; Hill J; Dusing RW; Shen X
Pract Radiat Oncol; 2017; 7(5):325-331. PubMed ID: 28377141
[TBL] [Abstract][Full Text] [Related]
23. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.
de Jong IJ; Pruim J; Elsinga PH; Vaalburg W; Mensink HJ
J Nucl Med; 2003 Mar; 44(3):331-5. PubMed ID: 12620996
[TBL] [Abstract][Full Text] [Related]
24. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.
Tilki D; Reich O; Graser A; Hacker M; Silchinger J; Becker AJ; Khoder W; Bartenstein P; Stief CG; Loidl W; Seitz M
Eur Urol; 2013 May; 63(5):792-6. PubMed ID: 22902037
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
27. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
28. Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer.
Zattoni F; Artioli P; Burei M; Chiaravalloti A; Chierichetti F; Donner D; Panareo S; Rambaldi I; Schillaci O; Dal Moro F; Evangelista L
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):167-173. PubMed ID: 34477346
[TBL] [Abstract][Full Text] [Related]
29. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
30. Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography.
Jilg CA; Schultze-Seemann W; Drendel V; Vach W; Wieser G; Krauss T; Jandausch A; Hölz S; Henne K; Reske SN; Grosu AL; Weber WA; Rischke HC
J Urol; 2014 Jul; 192(1):103-10. PubMed ID: 24518792
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
32. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
Lépinoy A; Cochet A; Cueff A; Cormier L; Martin E; Maingon P; Bosset JF; Brunotte F; Créhange G
Radiother Oncol; 2014 Apr; 111(1):120-5. PubMed ID: 24780635
[TBL] [Abstract][Full Text] [Related]
33. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A
Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269
[TBL] [Abstract][Full Text] [Related]
34. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy.
Winter A; Uphoff J; Henke RP; Wawroschek F
Urol Int; 2010; 84(4):418-23. PubMed ID: 20299773
[TBL] [Abstract][Full Text] [Related]
35. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
[TBL] [Abstract][Full Text] [Related]
36. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
[TBL] [Abstract][Full Text] [Related]
37. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
Ceci F; Herrmann K; Castellucci P; Graziani T; Bluemel C; Schiavina R; Vollmer C; Droll S; Brunocilla E; Mazzarotto R; Buck AK; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2222-31. PubMed ID: 25182750
[TBL] [Abstract][Full Text] [Related]
38. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
39. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
40. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
Würschmidt F; Petersen C; Wahl A; Dahle J; Kretschmer M
Radiat Oncol; 2011 May; 6():44. PubMed ID: 21529377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
